Gongying Powder is a non-sterile veterinary active pharmaceutical ingredient supplied as a white to off-white crystalline powder under model designation GP-VET-API-100. A micronized variant, GP-VET-API-100M, is available for suspension concentrates, injectable pre-filtration processing, and low-dose dry powder blends where content uniformity is sensitive to particle size distribution. The powder is packaged in sealed low-density polyethylene liners inside aluminum foil laminate bags at a net weight of 25 kg; custom packaging for aseptic transfer is available on request. Storage in unopened original containers is controlled room temperature not exceeding 25 °C, protected from light and moisture. Opened containers should be used within 30 days when stored at or below 60% RH; the lot-specific re-test interval is typically 24 months from manufacture. The material is not intended for direct administration and must be further processed under applicable veterinary GMP into tablets, capsules, injections, solutions, powders, granules, or premixes.

Incoming quality control should confirm identity by infrared spectroscopy or HPLC retention time, water content, particle size, and appearance before release to production. The active substance is not diluted with carriers, flow aids, or preservatives; therefore the mass balance in downstream formulation remains with the formulator.

Release specifications are lot-specific and route-dependent. The following representative framework is based on current Chinese Veterinary Pharmacopoeia and selected Ph. Eur. general chapters; it is not a substitute for the approved dossier.

Assay of the active substance is performed by HPLC using a stability-indicating method. Method suitability requires resolution between the main peak and known related substances not less than 2.0, tailing factor not more than 2.0, and relative standard deviation for replicate injections not more than 1.0%. Residual solvent analysis uses headspace gas chromatography; method quantification limits are established for Class 1 and Class 2 solvents per VICH GL18.

What Processing Constraints Appear in Direct Compression and Wet Granulation?

Direct compression of GP-VET-API-100 requires pre-blending with microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. Rotary tablet presses with 10 mm to 12 mm round flat-faced or standard concave tooling are used for development batches. Because the powder may exhibit an angle of repose above 40°, wet granulation is often preferred for higher-dose tablets. High-shear granulation is performed with an impeller tip speed of 2 m/s to 6 m/s and a chopper speed of 1000 rpm to 2000 rpm; these settings are starting points and require pilot confirmation because published data for this specific product under high-shear granulation is limited.

Wet massing endpoint is determined by impeller torque or power draw rather than fixed time; over-granulation produces fines and low-compressibility agglomerates. The wet mass is dried in a fluid-bed dryer with inlet air temperature not exceeding 60 °C unless forced-degradation data support higher exposure. Product temperature is monitored, and discharge moisture content is confirmed by loss on drying; a common target is 1% to 3%. Dried granulate is milled through a screen size of 1.0 mm and lubricated with 0.5%–1.0% magnesium stearate. Higher lubricant levels prolong disintegration time. Tablet hardness is adjusted in the range of 50 N to 80 N only after dissolution data confirm an acceptable release profile, because the API itself does not dictate a fixed hardness. Dissolution testing follows Apparatus 2 paddle at 50 rpm to 75 rpm in pH-adjusted media as described in the relevant veterinary monograph.

For capsules, granulate flow is quantified by Carr index and Hausner ratio; a Carr index below 20% is generally acceptable for automatic dosator or tamping disk filling. If flow is insufficient, the formulator may add colloidal silicon dioxide at 0.2%–0.5%, but this addition must be validated for content uniformity and dissolution.

Residual solvent analysis uses headspace gas chromatography with flame ionization or mass spectrometric detection. A 30 m × 0.25 mm × 1.4 µm 6% cyanopropylphenyl/94% dimethylpolysiloxane capillary column is a common screening configuration, but method suitability must be confirmed for the specific active substance. Class 1 solvents are controlled below the limits defined in VICH GL18; Class 2 solvents are reported against the same guidance. Peak purity for HPLC assay is evaluated by photodiode array detection from 200 nm to 400 nm; if the chromophore is weak, charged aerosol detection or evaporative light scattering may be required. The supplier certificate of analysis should include retention time, purity factor, and resolution from the nearest known related substance. X-ray powder diffraction may be used to confirm the polymorphic form if the active substance is crystalline, because different crystal forms can alter dissolution kinetics in tablet and suspension formulations.

Loss on drying and water content are distinct parameters: loss on drying may capture residual solvents and bound moisture, while Karl Fischer titration gives water specifically. For hygroscopic powders, water content above 2.0% may require pre-drying in a vacuum dryer at 40 °C to 50 °C until water content falls below 1.0%; however, the thermal stability of the active substance must be confirmed before drying. Published data for the specific active substance in Gongying Powder under vacuum drying is limited, so a pilot drying study is required.

Endotoxin and Membrane Compatibility Boundaries for Injection Solutions

For injectable dosage forms, the API is not sterile as supplied. The active substance is dissolved in Water for Injection under a controlled environment, then clarified and subjected to sterilizing filtration through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane. Membrane binding studies are required because low concentrations of the active substance may adsorb to some filter materials. Terminal moist heat sterilization at 121 °C for 15 minutes is applicable only after product-specific stability studies; if the active substance degrades under saturated steam, a lower-temperature cycle may be considered but must still meet the sterility assurance level required by the finished product monograph. Published data for this specific configuration is limited, so the manufacturer’s technical file and forced-degradation studies should be consulted before fixing the sterilization cycle.

Endotoxin limits are dose-dependent. The reduced-endotoxin grade is released with a bacterial endotoxin test performed according to Ph. Eur. 2.6.14, and the acceptance criterion is calculated from the maximum daily parenteral dose. Standard non-sterile oral/feed grades may contain higher bioburden and should not be used in injectable formulation without endotoxin reduction steps. Aseptic processing routes require environmental monitoring and process simulation under applicable GMP provisions; the API itself cannot compensate for inadequate aseptic technique.

For drinking water solutions, a stock solution is prepared at a concentration below the solubility limit of the active substance in non-chlorinated potable water below 30 °C. Gentle stirring at 20 °C to 30 °C is preferred over high-shear mixing to avoid foam formation. Chlorinated potable water can be used only if chlorine demand studies show no rapid degradation; free chlorine above 2 ppm may reduce assay in some active substances, so the water source should be tested. Hard water containing more than 300 ppm calcium carbonate equivalent may reduce solubility or accelerate precipitation; a jar test with the target water source is therefore part of preformulation. Solutions without a validated preservative system should be used within 24 hours after preparation to avoid microbial proliferation and potency loss.

When the Powder Is Compounded into Premix and Medicated Feed, What Homogeneity and Thermal Limits Apply?

Premix preparation requires geometric dilution with a low-moisture carrier such as calcium carbonate, corncob meal, or lactose monohydrate. The active concentration in the intermediate premix is typically 10 g/kg to 100 g/kg depending on the dosage regimen; the final feed carryover rate must be validated against mixer characteristics. Ribbon blenders or double-cone blenders are acceptable if mixing time and fill volume are validated by sampling at 10 evenly distributed points and assaying active content. A coefficient of variation below 5% is commonly required for medicated feed premixes, and first- and last-discharge samples must be verified to rule out segregation. If segregation occurs, the carrier particle size distribution should be adjusted or a flow conditioner added.

Dry carrier selection matters: porous carriers may absorb hygroscopic API and improve stability, but may also retard dissolution if the carrier binds the active substance. The selected carrier must be tested for pH, moisture, and heavy metals; carriers with high moisture can initiate hydrolysis during storage. If the active substance is light-sensitive or hygroscopic, the premix should be packaged in opaque, foil-lined bags and stored with desiccants to keep final moisture content below 5%.

Feed pelleting or extrusion can expose the API to frictional heat of 70 °C to 90 °C for 10 s to 30 s. If thermal degradation is observed by assay and related substances, the premix should be applied post-pellet by spraying onto cooled pellets or mixed into the finished mash feed. Because published data specific to Gongying Powder in extruded feed is limited, pilot-scale recovery studies are indispensable before routine production. The recovery assay should include a related substances determination, not only an active content assay, to detect trace degradation products that may affect safety or stability.

Compared with unmicronized APIs, the micronized GP-VET-API-100M lot has a finer particle size distribution and higher specific surface area; this may reduce disintegration time in tablets and support suspension uniformity, but it also increases electrostatic charge and dust generation. Processing areas should therefore include local exhaust ventilation or containment booths with dust collection. Unlike technical-grade raw powders, this product is released against a veterinary API specification that includes related substances, residual solvents, and microbial limits. Technical or feed additive grades may not carry the same batch-to-batch documentation; the absence of a full API release dossier means those materials can contain unidentified impurities or solvent residues that are not acceptable for injectable or food-producing animal use. A further difference is the absence of added carriers, glidants, or flavorings in GP-VET-API-100. A commercial water-soluble powder may already contain glucose, citric acid, or surfactants, which can simplify drinking water use but reduces flexibility in dose-tailored formulations. For parenteral routes, the optional reduced-endotoxin grade is the principal distinction; if not specified, standard non-sterile oral-grade material should not be used in injectable formulation. Each delivered lot includes a certificate of analysis under ISO 9001:2015 or equivalent quality management system, linking results to specific compendial methods and batch records. When a receiving site audited under EU GMP Part II or equivalent is used, the audit report may be requested; the API supplier should provide an open communication pathway for quality queries and lot-specific deviations.